Can You Mix Ozempic and Wegovy — and What's the Difference?

Are Ozempic and Wegovy actually the same drug?

In terms of active ingredient, yes. Both are semaglutide, a GLP-1 receptor agonist that slows gastric emptying, reduces appetite and influences blood-sugar regulation. The molecule itself is identical. What differs is the licensed purpose, the approved dose range, and therefore the product you receive.

Ozempic comes in doses up to 2mg weekly and is approved in the UK solely for type 2 diabetes. Wegovy reaches a 2.4mg weekly maintenance dose and carries a UK licence specifically for weight management alongside lifestyle changes. The NHS medicines page for Wegovy sets this out clearly, as does the MHRA's guidance distinguishing the two brand names. Prescribing Ozempic for weight loss would be off-label; prescribing Wegovy for someone without the relevant BMI criteria would not meet the licensed indication. Same molecule, different legal status for different conditions.

This distinction matters for anyone searching this topic, because it is common to hear the names used interchangeably. They are not interchangeable in clinical or regulatory terms. If you want to understand exactly how Ozempic and Wegovy compare in more depth, that page covers it fully.

Why would someone think about taking both at once?

Usually the question arises in one of two situations. Either someone has been prescribed Ozempic for diabetes and wonders whether adding Wegovy could accelerate weight loss, or they have read about Wegovy's results and are already on Ozempic and feel the dose is not doing enough.

In the first case, a prescriber managing type 2 diabetes would normally consider switching to a medicine that addresses both conditions, or adjusting the existing regimen, rather than layering a second semaglutide product. Taking Ozempic and Wegovy simultaneously simply doubles the semaglutide load: nausea, vomiting, diarrhoea and the risk of more serious events like acute pancreatitis all increase with dose. The MHRA's guidance on GLP-1 medicines is clear that these are not casual top-up medicines.

In the second case, the appropriate route is a clinical review, not a second prescription. Dose titration exists precisely to find the right level for a given person, and a prescriber assessing progress can adjust accordingly. Adding a second product bypasses that process entirely and creates risks the original prescriber cannot monitor.

There is also a practical point worth raising: anyone buying medicines like these from sellers who do not require a clinical consultation is operating outside the legal supply chain. The MHRA has warned publicly about counterfeit pens circulating online, some containing wholly different substances. A double-dose arrangement sourced informally compounds that risk considerably.

If Ozempic is not for weight loss, what IS licensed for it in the UK?

Two injectable medicines hold a UK licence for weight management in adults. Wegovy (semaglutide 2.4mg, and now up to 7.2mg following MHRA approval in early 2026) is licensed for adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition such as high blood pressure, high cholesterol or prediabetes. The second is Mounjaro (tirzepatide), a dual GIP and GLP-1 receptor agonist made by Eli Lilly, licensed across the same BMI thresholds.

In clinical trials, both medicines produced meaningful average weight loss when combined with a reduced-calorie diet and increased activity. NICE has recommended tirzepatide (TA1026) and previously recommended semaglutide for weight management (TA875) within specific NHS criteria, though private treatment is available without those thresholds being met, subject to a prescriber's assessment. Lower BMI thresholds apply under UK guidance for some ethnic backgrounds.

If you have been on Ozempic and a prescriber decides a switch to Wegovy is appropriate, that involves a clinical conversation about timing, current dose, and washout periods, it is not a straightforward swap. The page on moving from Ozempic to Wegovy covers what that process involves. For context on how the treatment costs of licensed weight-loss medicines compare, the treatment overview gives a useful starting point.

What should you actually do if you feel your treatment is not working?

Talk to whoever prescribed it. That sounds obvious, but a surprisingly large number of people try to solve it by sourcing additional supply rather than raising it with their clinical team. A question our prescribers hear regularly is whether a different medicine, a higher dose, or a switch in product would make a meaningful difference, and the answer depends entirely on the individual's history, current dose, tolerability and goals.

If your Ozempic prescription was issued for diabetes, your diabetes care team is the right first contact. If you are considering weight management treatment and have not yet started, a prescriber can assess which licensed option is suitable. The mechanism behind semaglutide-based medicines and how to access Wegovy through a regulated UK pharmacy are both worth reading before that consultation.

At nume, every consultation is read by a GPhC-registered Independent Prescriber (a real clinician reviewing your answers, not automated software) on the same day you submit, once you're clinically approved. No subscription, no hidden fees, and treatment dispatched the same day for next-working-day delivery. Monday morning tends to be our busiest window; if you submit by 12pm on a working day, dispatch happens the same afternoon. If you want to explore whether a licensed weight-loss treatment is right for you, start your free consultation with nume.